Member Info for CauldStream7

Nolupus, wildtiger.
Agree with your conclusions about Tim's interview. Not the usual eternally happy Tim but a more sober fellow this time. Perhaps someone at his elbow cautioning him against over promising, over optimism.
I, too, have been wondering what has happened to Sol about which Tim was so bullish in the summer. He was predicting joyous news about it by now.

4 RNS notifications in a week. A record?
I believe that this signals a determination on the part of the new Board to get things moving after years of indecision. I note the statement of Tim Franklin in the Corporate Update which focuses on the R and D operations of the labs in Bordeau of which he is now in charge. He's a man in a hurry, I think. So expect regular posts from him on the progress of the main candidates for the market.
I would also expect an early release of news about the PK study. Franklin, McCarthy and Baderoon that investors like us are worried at the lack of news. They know they have to put their money where their mouth is so they have to perform.

Pokerchips:
I also think you could be correct in your surmise.
I think that the promotion of Lisa B. to the Board might herald a more regular flow of news to investors. I expect there will be more product news to report and that the reports will be more realistic than some previous ones.

Lambo
You haven't a clue what the sp will be by Christmas or any other time. You are a scaremonger. If you have no knowledge of this share just keep your thoughts to yourself.

Gee whizz - what a bunch of imbecilic comments from Lambo and Mystic Mike, etc, esp. the former.
Why is Lambo worried about the lack of news of the PK study? Hasn't he read that it will take 8 - 12 weeks for results to come through? We are still only on week 7. And wasn't it made clear that they have to wait for min of one month to measure the trace amounts of Lupuzor in the bodies of the 24 volunteers who have been tested in the PK Trial? This is not a trial about swallowing sweets.
And what's the use of crying " I wish I had sold..." as per MM? I could also moan about past sell opportunities as in April 2018 when the price was over 150p before the crash. That's what they said after the Great Crash in 29. I've just got on and bought at the amazingly low prices of the past few months all thanks to the blindness or poverty of shareholders who are willing to sell at today's prices. Are they nuts?
If you look at the Corporate Update, they have ticked most of the boxes that I would have wanted: Reduced overheads by over half from next year; moved out the old guard and put Dr Franklin in charge of IMM France; got Prof Muller directly involved in the design in a new Phase 2/3 Trial of P140 for CIPD; got tighter commercialisation targets for the research programmes. And unless McCarthy and Franklin are deluding themselves and us, we are surely on track to getting FDA approval of the PK trial.
We should applaud the BOD for the first time in years for getting the company's priorities sorted out.

ALB1 and Reflex
When I am in a black mood over IMM's prospects and the performance of its CEO and BOD, I can't help feeling that after the gloom will come some cheer in time for Christmas. In my more optimistic spells I persuade myself to believe that there will be positive news about Lupuzor and about the drugs in the Ureka stable in the next Quarter.
So my prediction for the sp is 60p for Christmas. Enough for a fat turkey, and a Christmas pudding with lashings of brandy!
So, Cheer Up!

Kev.
I wish I could understand you.

Kev.
I wish I could understand you.

Wild tiger:
I admire your fortitude and I hope it is rewarded.
I wish putting a rocket under Tim/ IMM was as easy as applying a finger to a start button. Research results are slow to come through. Perhaps we will hear something to our advantage before the end of this month and surely more positive news re Lupuzor and Ureka Pharma by the end of this year.....or not!

Aventador: I don't believe that all or even most of today's "Sells" are that. Most likely they are Buys. On HL's platform today's Sell price is 7.70p and Buy 2.78p. So howcome some Sells are showing a price of 7.96p and several others above the Buy price of 7.78p?
Strange.

I made two share Buys today but they show as Sells.
I wonder why.
Also, why the host of small Buys yesterday - eg 14 x 25? Is it a game or has it a purpose?

dh2
Don't you think IMM has researched this and knows the answer already?

ALB1 continued.

Read the recent RNS to obtain the details of this small trial the results of which should be known by December. If this trial is successsful then the new Lupuzor P3 trial can begin.
Most shareholders find these delays, however explicable and "reasonable", to be very disappointing. This has led to downwards pressure on the sp which is why the price is now around 8p.
If you believe the positives in the IMM case outweight the negatives this price offers an incentive to buy now and make large profits later, probably starting the upward journey next year. But if you and probably the majority of shareholders think that this is a long, long road where promises are never going to be fulfilled, you will stay out of the ring.

ALB1
I'll do my best to answer your questions.
If you read through the results of the 2018 Phase 3 trial of Lupuzor you will see that there were two trial areas, one being Europe (including a special subset in Mauritius) and the other, the USA. The European cohort was much larger than the American one. In the European one the finding was that in patients with severe Lupus there was clear evidence of the efficacy of Lupuzor compared with the placebo. In the much smaller USA cohort, the opposite was true; if anything the placebo was more efficacious than Lupuzor. Very strange. I don't know why but it seems to me there was a ****-up in the selection of patients - were they really Lupus sufferers or merely showing similar symptoms to Lupus which has a wide range of symptoms making it difficult to diagnose.
18 months after this the research deal between Avion and IMM was signed; Avion was obviously persuaded by IMM that a properly conducted Phase 3 trial in the USA would produce the positive results that were found in the 2018 European part of the Phase 3 trial. Avion are not fools; they have a successful record of bringing drugs to the market after obtaining FDA approval and they were willing to commit $25 million to the new Phase 3 trial, more than double spent on the 2018 trial.
So the CEO of IMM is correct to claim that Lupuzor has been shown to work; what he didn't say was that this success in the large European patient cohort was negated by the failure in the much smaller USA patient cohort and led to the FDA negative view of the overall result.
Avion is a private company; it does not have to make known to the market any news which might influence the price of the share, whereas IMM has to make any such news known to the market, hence the long line of RNS announcements on the IMM and LSE websites. Avion only seems to inform shareholders of current success stories of its principal products already in the market.
As to the delay in starting a new Phase 3 Lupuzor trial, I think this can be attributed to two factors. The first is the Covid - 19 pandemic which led to pharma companies and state agencies such as the FDA concentrating their resources to the search
for new therapies and vaccines to treat Covid. The FDA were under tremendous pressure from the Trump adminsitration to give top priority to assessing various new therapies, including the efficacy of already approved drugs which were developed to treat other diseases like malaria and of the immune system. These included Trump's bizarre suggestions for treatment. I forget them all,but they included hydroxychloroquine for treating malaria, and bleach for cleaning lavatories.
At the same time, it seems as though the FDA wants to ensure that the debacle of the first Phase 3 trial involving American patients should not be repeated. Recent RNS announcements mention "productive discussions" between Avion and the FDA which led to the present situation where a small number (25) are being te

ALB1: All you have to do is look at the list of RNS announcements on this site. On the 28 November, 2019, a RNS was issued entitled "Licence Agreement for Lupuzor with Avion in US". This RNS provides full details of a licence and development agreement between Immupharma and Avion. The full details are set out as to the rights and duties of each party to the agreement and the stage payments Avion will make to IMM after the conclusion of a successful Phase 3 trial of Lupuzor the costs of which will met by Avion up to $25 million.
So do your own research before creating unfounded scare stories.

In his Proactive Interview last week Tim McCarthy announced that he would be visiting the labs of Ureka Pharma in France this week. He praised the scientists there and stressed the importance of their work in the context of the importance to IMM of having a stable of pharma products and not to rely solely on Lupuzor.
He said he would be visiting these labs this week. Let's hope that Lisa's higher profile as a member of the BOD will ensure that we receive an uptodate review of progress on Ureka's research programme. It could be very important for IMM's sp.

Frits
I think you are referring to the comments posted by Nolupus. I agree with you but it would help if you made it clear that he/she is the person is you have in mind.
I can't understand why IMM is getting blamed for the slowness of the FDA response which IMM can't do anything about. Ultimately, one has to accept that drugs that are being brought forward for approval by FDA to deal with Covid-19 are to blame for the delays.

On target: Do you mean sail on?

Supermobileman.
Thanks for bringing up Nolupus's remarks about IMM's alleged bias against French speakers. We have ignored for too long his sly insinuations against IMM and Lupuzor. What is his game plan?

Nolupus: When it comes to throwing mud you lead the field. Remember Eva? It seemed to me that you tossed quite a bit of dirt in her direction in days gone by.